Subscribe

Articles

FDA Approves Yervoy to Reduce the Risk of Melanoma Returning After Surgery
FDA Updates, In the News
Web Exclusives
Today the US Food and Drug Administration (FDA) expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery. Read More ›
FDA Approves New Treatment for Advanced Pancreatic Cancer
FDA Updates, In the News
Web Exclusives
The US Food and Drug Administration (FDA) today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. Read More ›
FDA Approves First-of-Its-Kind Product for the Treatment of Melanoma
FDA Updates, In the News
Web Exclusives
The US Food and Drug Administration today approved Imlygic (talimogene laherparepvec), the first FDA approved oncolytic virus therapy, for the treatment of melanoma lesions in the skin and lymph nodes. Read More ›
FDA Approves Yervoy to Reduce the Risk of Melanoma Returning After Surgery
FDA Updates, In the News
Web Exclusives
Today the US Food and Drug Administration (FDA) expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma, to lower the risk that the melanoma will return following surgery. Read More ›
FDA Approves New Treatment for Advanced Pancreatic Cancer
FDA Updates, In the News
Web Exclusives
The US Food and Drug Administration (FDA) today approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy. Read More ›
FDA Approves New Therapy for Certain Types of Advanced Soft Tissue Sarcoma
FDA Updates, In the News
Web Exclusives
The US Food and Drug Administration (FDA) today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS)—liposarcoma and leiomyosarcoma—that cannot be removed by surgery (unresectable) or is advanced (metastatic). Read More ›
Opioid-Induced Constipation
Opioid-Induced Constipation
By Amanda R. McFee Winans, PharmD, BCPS; Jayne Pawasauskas, PharmD, BCPS; Leah Sera, PharmD, BCPS
Online First, Supportive Care
Author Preview Section
This section provides a quick update of symptomatic conditions in oncology and their management. Readers are invited to submit brief updates following the guidelines provided within. Read More ›
Supportive Care in the Oncology Setting
Supportive Care in the Oncology Setting
By Margaret Rummel, BSN, RN, MHA, OCN
Best Practices in Patient Navigation - Second Issue: Supportive Care Edition
There are numerous complications that may develop in patients with cancer; some are related to the disease itself, whereas others are associated with agents or combination regimens used during the course of treatment. Read More ›
The Role of the Oncology Nurse Navigator in Improving Supportive Care
The Role of the Oncology Nurse Navigator in Improving Supportive Care
By Barbara Rogers, CRNP, MN, AOCN, ANP-BC
Supportive Care
Best Practices in Patient Navigation - Second Issue: Supportive Care Edition
A nurse/patient navigator is defined by the Academy of Oncology Nurse & Patient Navigators as “a medical professional whose clinical expertise and training guides patients and their caregivers to make informed decisions, collaborating with a multidisciplinary team to allow for timely cancer screening, diagnosis, treatment, and increased supportive care across the cancer continuum.” Read More ›
Pembrolizumab FDA Approved in Patients with Advanced Lung Cancer
FDA Updates, In the News
The US Food and Drug Administration (FDA) granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non–small-cell lung cancer (NSCLC) whose disease has progressed after other treatments, and with tumors that express a protein called PD-L1. Read More ›

Page 210 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, TON print publication, and TON Bi-Weekly e‑newsletter.

Subscribe

Amplity

© Amplity, Inc. All Rights Reserved. Privacy Policy.